Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Although Novo was first to market with Wegovy and its sister drug Ozempic for ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.